The Secret Reason AMGN Is A Strong BuyAmgen Inc.BATS:AMGNPEKBITAmgen's fundamental value proposition is currently anchored by strong financial execution and a highly transformative pharmaceutical pipeline that positions the company for significant long-term revenue acceleration The primary growth catalyst remains MariTide which is Amgen's investigational monthly injectable therapy for obesity and diabetes that is currently progressing through late-stage Phase 3 clinical trials and threatens to disrupt the current weekly market duopoly by offering superior patient adherence and convenience Beyond metabolic health Amgen has successfully diversified its portfolio with critical advancements in oncology and rare diseases including recent regulatory approvals for IMDYLLTRA in small cell lung cancer and strong clinical momentum for UPLIZNA and TAVNEOS which effectively mitigates the risk of upcoming patent expirations on older blockbusters like Prolia and Enbrel Financially the company continues to demonstrate immense resilience and cash generation capability with recent quarterly revenues rising by 6% to 8.6 billion dollars driven by double-digit volume growth across 16 core brands alongside a substantial increase in Free Cash Flow which reached 1.5 billion dollars compared to 1.0 billion in the previous year This robust cash flow ensures that Amgen can comfortably fund its intensive Research and Development programs while maintaining its commitment to a reliable and growing dividend payout which remains a key attraction for institutional investors From a valuation perspective Amgen maintains a high operating margin that is well above the healthcare sector average yet the stock trades at a reasonable forward Price-to-Earnings multiple around 23x to 24x which suggests that the market has not fully priced in the immense commercial potential of MariTide and the expanding oncology portfolio The combination of steady current cash flows and the massive asymmetric upside from the global weight-loss and oncology markets makes Amgen a compelling fundamental investment as conservative consensus estimates are likely to face upward revisions as Phase 3 clinical data continues to mature